Remove development drug-approvals
article thumbnail

Made In Victoria: a groundbreaking peanut allergy therapy

Manufacturer's Monthly

Minister for Economic Growth Tim Pallas announced Breakthrough Victoria’s $12 million investment into Aravax as part of a $66 million funding round to develop a novel peanut allergy treatment. Aravax has received approval from the U.S

article thumbnail

Frost & Sullivan Awarded Duopharma Biotech with the 2022 Malaysian Company of the Year Award

Frost & Sullivan Manufacturing

Duopharma Biotech delivers accessible and affordable healthcare to the Malaysian population by leveraging biosimilars, which are scientifically approved alternatives to drugs derived from biological sources. Biosimilars typically cost between $100 million and $200 million to develop, while original drugs cost around $2.6

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Karl Storz enters talks to acquire surgical robot developer Asensus Surgical

Robotics Business Review

Asensus and Karl Storz began ollaborating on plans for development and marketing just over a year ago. That included potential collaborations and licensing transactions, a “go-it-alone” strategy reliant upon significant fundraising, a sale of the company, or additional development transactions. That represents a 66.7%

article thumbnail

JAMP Pharma Group acquires a mfg. facility in Lévis, Que.

Canadian Manufacturing

This acquisition thus strengthens the Canadian supply chain and contributes to addressing drug shortages, an issue that was particularly highlighted during the pandemic. Currently, only 12% of pharmaceutical products consumed by Canadians are made domestically.

article thumbnail

Bushu Pharma Recognized with Frost & Sullivan’s 2023 Japan Customer Value Leadership Award for Offering Advanced Pharmaceutical Manufacturing and Robust Supply Chain Solutions

Frost & Sullivan Manufacturing

SAN ANTONIO – November 30, 2023 – Frost & Sullivan recently researched the contract development and manufacturing organization industry and, based on its findings, recognizes Bushu Pharma with the 2023 Japan Customer Value Leadership Award. The company also takes a unique approach to its technology, product, and service development.

article thumbnail

Seno Medical Earns Frost & Sullivan’s 2023 United States Enabling Technology Leadership Award for Delivering a More Efficient Breast Cancer Diagnosis with Its Cutting-edge Technology

Frost & Sullivan Manufacturing

Its Imagio® Breast Imaging System, which received Pre-Market Approval (PMA) from the US Food and Drug Administration (FDA) in 2021, seamlessly combines opto-acoustics and ultrasound to provide clinicians with real-time results. Furthermore, Seno Medical’s strategy extends beyond just technology development.

article thumbnail

Fusion Pharmaceuticals provides manufacturing update

Canadian Manufacturing

a clinical-stage oncology company focused on developing radiopharmaceuticals as precision medicines, announced progress with its FPI-2265 development program, an update on FPI-1434 Phase 1 Cohort 2 data and the production of the first clinical doses at the Company’s proprietary manufacturing facility.